Advisory Committee on the Medical Uses of Isotopes: Renewal Notice, 15779-15780 [2014-06200]

Download as PDF Federal Register / Vol. 79, No. 55 / Friday, March 21, 2014 / Notices Notice of Intent To Grant Exclusive License. ACTION: NATIONAL AERONAUTICS AND SPACE ADMINISTRATION This notice is issued in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to grant an exclusive license in the United States to practice the invention described and claimed in USPN 6,997,637, Deceleration-Limiting Roadway Barrier, NASA Case No. MSC– 23178–1 to LifeNet Systems Inc., having its principal place of business in Wellborn, Florida. The patent rights in this invention have been assigned to the United States of America as represented by the Administrator of the National Aeronautics and Space Administration. The prospective exclusive license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. SUMMARY: The prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, NASA receives written objections including evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Competing applications completed and received by NASA within fifteen (15) days of the date of this published notice will also be treated as objections to the grant of the contemplated exclusive license. Objections submitted in response to this notice will not be made available to the public for inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. DATES: Objections relating to the prospective license may be submitted to Patent Counsel, Office of Chief Counsel, NASA Johnson Space Center, 2101 NASA Parkway, Houston, Texas 77058, Mail Code AL; Phone (281) 483–3021; Fax (281) 483–6936 ADDRESSES: Ms. Michelle P. Lewis, Technology Transfer and Commercialization Office/AO52, Johnson Space Center, Houston, TX 77058, (281) 483–8051. Information about other NASA inventions available for licensing can be found online at https://technology.nasa.gov. mstockstill on DSK4VPTVN1PROD with NOTICES FOR FURTHER INFORMATION CONTACT: Sumara M. Thompson-King, Deputy General Counsel. [FR Doc. 2014–06156 Filed 3–20–14; 8:45 am] BILLING CODE 7510–13–P VerDate Mar<15>2010 17:18 Mar 20, 2014 Jkt 232001 [Notice (14–030)] NASA Advisory Council; Aeronautics Committee; Meeting National Aeronautics and Space Administration. ACTION: Notice of meeting. AGENCY: In accordance with the Federal Advisory Committee Act, Public Law 92–463, as amended, the National Aeronautics and Space Administration announces a meeting of the Aeronautics Committee of the NASA Advisory Council. This Committee reports to the NAC. The meeting will be held for the purpose of soliciting, from the aeronautics community and other persons, research and technical information relevant to program planning. SUMMARY: Thursday, March 27, 2014, 9:00 a.m. to 5:00 p.m.; Friday, March 28, 2014, 9:00 a.m. to 12:15 p.m.; Local Times DATES: NASA Headquarters, Room 6E40, 300 E Street SW., Washington, DC 20546. FOR FURTHER INFORMATION CONTACT: Ms. Susan L. Minor, Executive Secretary for the Aeronautics Committee, NASA Headquarters, Washington, DC 20546, (202) 358–0566, or susan.l.minor@ nasa.gov. ADDRESSES: The meeting will be open to the public up to the capacity of the room. Any person interested in participating in the meeting by WebEx and telephone should contact Ms. Susan L. Minor at (202) 358–0566 for the web link, tollfree number and passcode. The agenda for the meeting includes the following topics: • NAC Aeronautics Committee Work Plan. • NASA Aeronautics FY 2015 President’s Budget Request. • Aeronautics Research Mission Directorate Program Organization. • Fundamental Aeronautics Program Foundational Technologies. • University Engagement. • System-Wide Safety Assurance Thrust Overview. Attendees will be requested to sign a register and to comply with NASA security requirements, including the presentation of a valid picture ID to Security before access to NASA Headquarters. Foreign nationals attending this meeting will be required to provide a copy of their passport and visa in addition to providing the SUPPLEMENTARY INFORMATION: PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 15779 following information no less than 3 working days prior to the meeting: Full name; gender; date/place of birth; citizenship; visa information (number, type, expiration date); passport information (number, country, expiration date); employer/affiliation information (name of institution, address, country, telephone); title/ position of attendee; and home address to Susan Minor, NASA Advisory Council Aeronautics Committee Executive Secretary, fax (202) 358–4060. U.S. citizens and Permanent Residents (green card holders) are requested to submit their name and affiliation 3 working days prior to the meeting to Susan Minor at (202) 358–0566. It is imperative that these meetings be held on this date to accommodate the scheduling priorities of the key participants. This meeting will take place with less than 15 calendar days’ notice due to the delay in the announcement of the FY 2015 Budget Request and associated activities. Patricia D. Rausch, Advisory Committee Management Officer, National Aeronautics and Space Administration. [FR Doc. 2014–06202 Filed 3–20–14; 8:45 am] BILLING CODE 7510–13–P NUCLEAR REGULATORY COMMISSION Advisory Committee on the Medical Uses of Isotopes: Renewal Notice U.S. Nuclear Regulatory Commission. ACTION: This notice is to announce the renewal of the Advisory Committee on the Medical Uses Isotopes (ACMUI) for a period of two years. AGENCY: The U.S. Nuclear Regulatory Commission (NRC) has determined that the renewal of the Charter for the Advisory Committee on the Medical Uses of Isotopes for the two year period commencing on March 14, 2014, is in the public interest, in connection with duties imposed on the Commission by law. This action is being taken in accordance with the Federal Advisory Committee Act, after consultation with the Committee Management Secretariat, General Services Administration. The purpose of the ACMUI is to provide advice to NRC on policy and technical issues that arise in regulating the medical use of byproduct material for diagnosis and therapy. Responsibilities include providing SUPPLEMENTARY INFORMATION: E:\FR\FM\21MRN1.SGM 21MRN1 15780 Federal Register / Vol. 79, No. 55 / Friday, March 21, 2014 / Notices guidance and comments on current and proposed NRC regulations and regulatory guidance concerning medical use; evaluating certain non-routine uses of byproduct material for medical use; and evaluating training and experience of proposed authorized users. The members are involved in preliminary discussions of major issues in determining the need for changes in NRC policy and regulation to ensure the continued safe use of byproduct material. Each member provides technical assistance in his/her specific area(s) of expertise, particularly with respect to emerging technologies. Members also provide guidance as to NRC’s role in relation to the responsibilities of other Federal agencies as well as of various professional organizations and boards. Members of this Committee have demonstrated professional qualifications and expertise in both scientific and non-scientific disciplines including nuclear medicine; nuclear cardiology; radiation therapy; medical physics; nuclear pharmacy; State medical regulation; patient’s rights and care; health care administration; and Food and Drug Administration regulation. For further information please contact: Sophie Holiday, Office of Federal and State Materials and Environmental Management Programs, U.S. Nuclear Regulatory Commission, Washington, DC 20555; Telephone (301) 415–7865; email Sophie.Holiday@ nrc.gov. Dated at Rockville, Maryland, this 14th day of March, 2014. For the U.S. Nuclear Regulatory Commission. Andrew L. Bates, Federal Advisory Committee Management Officer. [FR Doc. 2014–06200 Filed 3–20–14; 8:45 am] BILLING CODE 7590–01–P SECURITIES AND EXCHANGE COMMISSION mstockstill on DSK4VPTVN1PROD with NOTICES [Release No. 34–71725; File No. SR–NSCC– 2014–03] Self-Regulatory Organizations; National Securities Clearing Corporation (‘‘NSCC’’); Notice of Filing of Proposed Rule Change To Enhance the System That Processes Corporate Actions Within NSCC’s Continuous Net Settlement (‘‘CNS’’) System March 14, 2014. Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 VerDate Mar<15>2010 17:18 Mar 20, 2014 Jkt 232001 (‘‘Act’’) 1 and Rule 19b–4 thereunder,2 notice is hereby given that on March 6, 2014, National Securities Clearing Corporation (‘‘NSCC’’) filed with the Securities and Exchange Commission (‘‘Commission’’) the proposed rule change as described in Items I, II and III below, which Items have been prepared by NSCC. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons. I. Clearing Agency’s Statement of the Terms of Substance of the Proposed Rule Change The proposed rule change consist [sic] of amendments to the Rules & Procedures (‘‘Rules’’) of NSCC to enhance the system that processes corporate actions within NSCC’s Continuous Net Settlement (‘‘CNS’’) system, as more fully described below. II. Clearing Agency’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change In its filing with the Commission, NSCC included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. NSCC has prepared summaries, set forth in sections A, B and C below, of the most significant aspects of such statements. (A) Clearing Agency’s Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change 1. Purpose NSCC has recently enhanced the system that applies corporate actions to Members’ open failed positions within CNS. While the enhancements to corporate action processing would not require NSCC Members to make any coding changes, NSCC is proposing to update Procedure VII of its Rules in order to reflect these enhancements. One of NSCC’s core service as a central counterparty is trade clearance and settlement through CNS, where compared and recorded transactions in eligible securities 3 for a particular settlement date are netted by issue into one net long (buy) or net short (sell) 1 15 U.S.C. 78s(b)(1). CFR 240.19b–4. 3 To be CNS-eligible, a security must be eligible for book-entry transfer on the books of The Depository Trust Company (‘‘DTC’’), an NSCC affiliate, and must be capable of being processed in the CNS system; for example, securities may be ineligible for CNS processing due to certain transfer restrictions (i.e., 144A securities) or due to the pendency of certain corporate actions. 2 17 PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 position. As a continuous net system, those positions are further netted with positions of the same issue that remain open after their originally scheduled settlement date (usually T+3), so that trades scheduled to settle on any day are netted with fail positions to result in a single deliver or receive obligation for each Member for each issue in which it has activity. As part of the services offered to NSCC Members, certain corporate actions, including cash dividends, stock dividends, bond interest, and other mandatory corporate actions (which include redemptions, stock and cash mergers, and name changes) are automatically debited or credited to Member’s CNS accounts with open fail positions in CNS. Members are also permitted to take part in certain voluntary corporate actions, which include tender or exchange offers, with respect to open fail positions in CNS. Enhancements to the processing of corporate actions within CNS, described below, would provide Members with more timely and detailed information regarding applicable corporate action events, would support additional corporate action events, and would provide short Members (i.e. Members that have failed to deliver securities to CNS) with information on their final liability on the same day that liability is applied to their CNS account. The proposed enhancements would also provide NSCC staff with an improved ability to monitor and process voluntary corporate action events. These enhancements are reflected in the proposed rule changes on Exhibit 5 4 hereto and are described below. Optional Dividends When a fail position in CNS is subject to a dividend payment, the issuer will specify the form in which that dividend will be paid (i.e. in securities or cash), called the ‘‘default option’’. NSCC long Members (i.e. Members that have failed to receive securities from CNS) may elect a form of payment that differs from the default option by submitting an instruction to NSCC no later than a preset date and cut-off time. While these elections are submitted manually today, under the enhancements to the processing of corporate actions, these elections would be submitted to NSCC electronically. Today, NSCC sets a cut-off time that is based on the cut-off time set by DTC for the submission of these instructions. 4 See Exhibit 5 of the Proposed Rule Change Filing, available at https://www.sec.gov/rules/sro/ nscc.shtml under File No. SR–NSCC–2014–04, Additional Materials. E:\FR\FM\21MRN1.SGM 21MRN1

Agencies

NUCLEAR REGULATORY COMMISSION

[Federal Register Volume 79, Number 55 (Friday, March 21, 2014)]
[Notices]
[Pages 15779-15780]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-06200]


=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION


Advisory Committee on the Medical Uses of Isotopes: Renewal 
Notice

AGENCY: U.S. Nuclear Regulatory Commission.

ACTION: This notice is to announce the renewal of the Advisory 
Committee on the Medical Uses Isotopes (ACMUI) for a period of two 
years.

-----------------------------------------------------------------------

SUPPLEMENTARY INFORMATION: The U.S. Nuclear Regulatory Commission (NRC) 
has determined that the renewal of the Charter for the Advisory 
Committee on the Medical Uses of Isotopes for the two year period 
commencing on March 14, 2014, is in the public interest, in connection 
with duties imposed on the Commission by law. This action is being 
taken in accordance with the Federal Advisory Committee Act, after 
consultation with the Committee Management Secretariat, General 
Services Administration.
    The purpose of the ACMUI is to provide advice to NRC on policy and 
technical issues that arise in regulating the medical use of byproduct 
material for diagnosis and therapy. Responsibilities include providing

[[Page 15780]]

guidance and comments on current and proposed NRC regulations and 
regulatory guidance concerning medical use; evaluating certain non-
routine uses of byproduct material for medical use; and evaluating 
training and experience of proposed authorized users. The members are 
involved in preliminary discussions of major issues in determining the 
need for changes in NRC policy and regulation to ensure the continued 
safe use of byproduct material. Each member provides technical 
assistance in his/her specific area(s) of expertise, particularly with 
respect to emerging technologies. Members also provide guidance as to 
NRC's role in relation to the responsibilities of other Federal 
agencies as well as of various professional organizations and boards.
    Members of this Committee have demonstrated professional 
qualifications and expertise in both scientific and non-scientific 
disciplines including nuclear medicine; nuclear cardiology; radiation 
therapy; medical physics; nuclear pharmacy; State medical regulation; 
patient's rights and care; health care administration; and Food and 
Drug Administration regulation.
    For further information please contact: Sophie Holiday, Office of 
Federal and State Materials and Environmental Management Programs, U.S. 
Nuclear Regulatory Commission, Washington, DC 20555; Telephone (301) 
415-7865; email Sophie.Holiday@nrc.gov.

    Dated at Rockville, Maryland, this 14th day of March, 2014.

    For the U.S. Nuclear Regulatory Commission.
Andrew L. Bates,
Federal Advisory Committee Management Officer.
[FR Doc. 2014-06200 Filed 3-20-14; 8:45 am]
BILLING CODE 7590-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.